Section 10
Therapy: Access & Reimbursement
Developing an effective therapy is the first step — ensuring that patients can access and afford these treatments is equally important.
The process of access and reimbursement involves multiple steps, including regulatory approvals, pricing negotiations, and integration into healthcare systems. This process is especially complex for rare diseases, where high development costs and small patient populations present unique challenges.
To accelerate access to innovative therapies, early engagement with regulatory bodies, health insurers, and policymakers is crucial. Streamlined reimbursement pathways, outcome-based pricing models, and real-world evidence collection help ensure that new treatments reach patients faster.
By improving these processes, we aim to reduce delays, enhance affordability, and ultimately improve patient outcomes.
How this accelerates therapy and care:
- Ensures faster availability of innovative treatments for patients.
- Supports sustainable pricing and reimbursement models for new therapies.
- Facilitates collaboration between industry, healthcare providers, and policymakers to improve patient access.
The Emma CPM is a center of expertise at the Amsterdam UMC focusing on patients and families with a rare genetic disorder.
A collaboration between the Emma Children's Hospital, the Department of Human Genetics, the Laboratory of Genetic Metabolic Diseases, and various departments and laboratories.